NCT06006858 - Post Authorization Safety Study Moderna COVID-19 Primary Vaccine | Biotech Hunter

Enrollment

1,284

Participants

Timeline

Start Date

November 3, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

March 31, 2023

Conditions

COVID-19

Interventions

BIOLOGICAL

Moderna COVID-19 Vaccine

Moderna COVID-19 Vaccine is provided as a white to off-white suspension for intramuscular injection. Each 0.5 mL dose of Moderna COVID-19 Vaccine contains 100 mcg of nucleoside-modified messenger RNA (mRNA) encoding the pre-fusion stabilized Spike glycoprotein (S) of SARS-CoV-2 virus.

Trial Locations (18)

10130

Gambir Public Health Center, Jakarta Pusat

10560

Johar Baru Public Health Center, Jakarta Pusat

10570

Cempaka Putih Public Health Center, Jakarta Pusat

10640

Kemayoran Public Health Center, Jakarta Pusat

11480

Palmerah Public Health Center, Jakarta

11530

Kebon Jeruk Public Health Center, Jakarta

11730

Cengkareng Public Health Center, Jakarta

12240

Kebayoran Lama Public Health Center, Jakarta

12820

Tebet Public Health Center, Jakarta

12980

Setiabudi Public Health Center, Jakarta

13260

Pulo Gadung Public Health Center, Jakarta

13420

Duren Sawit Public Health Center, Jakarta

13440

Regional Hospital Duren Sawit, Jakarta

13510

Kramat Jati Public Health Center, Jakarta

14120

Cilincing Public Health Center, Jakarta

14260

Koja Public Health Center, Jakarta

14310

Tanjung Priok Public Health Center, Jakarta

14410

Pademangan Public Health Center, Jakarta